Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392379 · ClinicalTrials.gov registry record · Phase 3
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT00392379: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT00392379 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 270 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392379, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.
Interventions
- DRUG Placebo lozenge
- DRUG Nicotine Lozenges
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392379
The ClinicalTrials.gov registry entry for NCT00392379 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo lozenge is the first listed.
NCT00392379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392379 about?
NCT00392379 is a clinical study titled "Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction". This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be rando...
What is the current status of trial NCT00392379?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2007-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00392379?
The interventions under investigation include: Placebo lozenge (DRUG), Nicotine Lozenges (DRUG).
Who is sponsoring clinical trial NCT00392379?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.